ChartRow logo
REGN
Regeneron Pharmaceuticals Inc.Stock · Healthcare · Nasdaq-100 0.5% · S&P 500 0.1%
$805.86+$2.38 (+0.30%)as of Aug 18, 3:55 PM ET
☾ After hours:$810.24+0.00%3:59 PM ET
CompareLLYUNHJNJABBVISRGTMO

REGN financial statements

The full income statement, balance sheet, and cash-flow statement for Regeneron Pharmaceuticals Inc. (REGN), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Shares outstanding (point-in-time)

2024-06 110.2M2024-09 109.9M2024-12 109.3M2025-03 108.0M2025-06 106.0M2025-09 105.1M2025-12 105.7M2026-03 104.8M2026-06 103.0M-6.6% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

About this data

Source: REGN's SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn't file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all REGN filings on SEC EDGAR → Not investment advice.